CD274 and cancer: A recent systemic review and meta-analysis involving more than 10 cancer types, including HNSCC, has shown that both mIHC/mIF had higher diagnostic accuracy in predicting clinical response to anti-PD-1/PD-L1 immunotherapy than PD-L1, TMB, or different gene expression signatures alone.